Yaz›flma Adresi / Address for Correspondence
Yüklə 369,37 Kb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- [CrossRef]
- Aygen B et al.
- [Cross- Ref]
|
[CrossRef] 68. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. He-
69. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b the- rapy in acute hepatitis C: impact of onset of therapy on sustai- ned virologic response. Gastroenterology. 2006; 130(3): 632-8. [CrossRef] 70. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
71. Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treat- ment of acute hepatitis C virus infection. Infect Dis Clin North
72. Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatology Res. 2006; 36(3): 201-8. [CrossRef] 73. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic res- ponse is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 139(5): 1593-601.
74. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus in- fection. J Gastroenterol Hepatol. 2007; 22(5): 615-33.
75. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J
76. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65.
77. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of ba- seline parameters and viral dynamics during therapy. Hepato- logy. 2003; 37(3): 600-9. [CrossRef] 78. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Alb- recht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepa- tology. 2003; 38(3): 645-52. [CrossRef] 79. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl
80. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, et al. Anemia during treatment with pe- ginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013; 57(3): 974-84. [CrossRef] 81. ACIP Adult Immunization Work Group, Bridges CB, Woods L, Coyne-Beasley T; Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older-United States, 2013. MMWR Surveill Summ. 2013; 62(Suppl. 1):9-19. 82. Shantha S, Thyagarajan SP, Premavathy RK, et al. Correlation of autoimmune reactivity with hepatitis B and C virus (HBV and HCV) infection in histologically proven chronic liver diseases. In- dian J Med Microbiol. 2002; 20(1): 12-5. 83. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between he- patitis C virus infection and type 2 diabetes mellitus: meta-analy- sis. World J Gastroenterol. 2012; 18(14): 1642-51. [CrossRef] 84. Lin CY, Sheen IS, Chen JY, et al. Various predictors of sustained virologic response in different age groups of patients with genoty- pe-1 chronic hepatitis C. J Clin Gastroenterol. 2013; 47(9): 794-9. [CrossRef] 85. Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibro- sis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013; 57(2): 240-6. [CrossRef] 86. Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El- Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal. 2013; 27(2): 121-9. [CrossRef] 87. Sporea I, Sirli R, Deleanu A, et al. Comparison of the liver stiff- ness measurement by transient elastography with the liver bi- opsy. World J Gastroenterol. 2008; 14(42): 6513-7. [CrossRef] 88. Goldberg E, Chopra S. Cirrhosis in adults: overview of complica- tions, general management, and prognosis [İnternet]. Waltham, MA: UpToDate, Inc. [erişim 2 Haziran 2014]. http://www.uptoda- te.com/contents/cirrhosis-in-adults-overview-of-complications- general-management-and-prognosis?source=search_result&se arch=compensated+cirrhosis&selectedTitle=1~150 89. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obvia- tes a protease inhibitor. Hepatology. 2014; 59(1): 71-7. [CrossRef] 90. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta- analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ri- bavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103.
91. Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol. 2013; 19(47): 8924-8. [CrossRef] 92. Feld JJ. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV in- fection. Best Pract Res Clin Gastroenterol. 2012; 26(4): 429-44. [CrossRef] 93. Niederau C, Mauss S, Boker K, et al. Noncompliance with guide- lines for the treatment of hepatitis C is frequent in daily practice.
94. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1207-17. [CrossRef] 95. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25): 2417-28.
96. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801. [CrossRef] 97. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401. [CrossRef] 98. Recommendations for Testing Managing, and Treating Hepa- titis C: Initial Treatment of HCV Infection [İnternet]. Alexandria and Arlington, VA: American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America
(IDSA) [erişim 26 Mart 2014]. http://www.hcvguidelines.org/full- report/initial-treatment-hcv-infection. 99. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) cir- culates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66(5): 3225-9. 100. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014; 34(Suppl. 1): 69-78.
101. Vermehren J, Sarrazin C. The role of resistance in HCV treat- ment. Best Pract Res Clin Gastroenterol. 2012; 26(4): 487-503.
102. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT- 1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Che- mother. 2009; 53(5): 2129-32. [CrossRef] 103. Sayan M. Proteaz inhibitörlerinde Türkiye direnç analizi [DVD]. In: Kronik Hepatit C: Yeni Gelişmeler ve Türkiye Deneyimi (21 Eylül 2013, İstanbul) Atölye Çalışması. İstanbul: Türk Klinik Mik- robiyoloji ve İnfeksiyon Hastalıkları Derneği, 2013. 104. De Meyer S, Thys K, Dierynck I, Ghys A, Aerssens J, Picchio G. Deep sequencing screening for telaprevir-resistant viral variants in previous null responders fails to identify those patients at risk of failing telaprevir plus peginterferon/ribavirin therapy. J Hepa-
105. Andonov A, Kadkhoda K, Osiowy C, Kaita K. Pretreatment resis- tance to hepatitis C virus protease inhibitors boceprevir/telap- revir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Can J Gastroenterol. 2013; 27(7): 414-6. 106. Hoffmann L, Ramos JA, Souza EV, et al. Dynamics of resistan- ce mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J. 2013; 10: 57. [CrossRef] 107. Palanisamy N, Danielsson A, Kokkula C, et al. Implications of ba- seline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013; 99(1): 12-7. [CrossRef] 108. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimic-
109. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 he- patitis C virus replication in patients. Hepatology. 2007; 46(3): 631-9. [CrossRef] 110. Kieffer TL, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolu- tion in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PloS One. 2012; 7(4): e34372. [CrossRef] 111. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to bocepre- vir. Gastroenterology. 2012; 143(3): 608-18 e1-5. 112. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pret- reatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139(1): 120-9 e18. 113. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alp- ha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann
114. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5): 954-60. [CrossRef]
115. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135(2): 451-8. [CrossRef]
116. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment vire- mia. J Hepatol. 2006; 44(1): 97-103.
117. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized cont- rolled trial. Hepatology. 2008; 47(1): 43-50. [CrossRef] 118. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathu- rin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol. 2010; 52(1): 25-31. [CrossRef] 119. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sus- tained virologic response in hepatitis B and C. J Hepatol. 2008; 49(4): 634-51. [CrossRef] 120. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepati- tis C therapy in non-genotype 1 patients: the near future. J Viral
121. Sung H, Chang M, Saab S. Management of hepatitis C anti- viral therapy adverse effects. Curr Hepat Rep. 2011; 10(1): 33-40.
[CrossRef] 122. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes in ultrasound morphology during antivi- ral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat. 2009; 16(3): 168-77.
123. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin- induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002; 16(9): 1623-32. [CrossRef] 124. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previo- usly treated chronic HCV infection. N Engl J Med. 2010; 362(14): 1292-303. [CrossRef] 125. Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013; 149(2): 152-8.
126. Hofmann WP, Chung TL, Osbahr C, et al. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-alp- ha and the protease inhibitors boceprevir or telaprevir. Antivir Ther. 2011; 16(5): 695-704. 127. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untre- ated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1195-206. [CrossRef] 128. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treat- ment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014; 39(5): 478-87. [CrossRef] 129. Dienstag JL. Chronic viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and
hill Livingstone Elsevier, 2010: 1593-617. [CrossRef] 130. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interfe- ron and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol. 2006; 21(1 Pt. 2): 319-26. [CrossRef] 131. Aygen B. Kronik hepatit C’de tedavi ve izlem. In: Köksal İ, Leb- lebicioğlu H, eds. Kronik Hepatitlerin Tedavisinde Güncel Yakla-
132. Recommendations for Testing Managing, and Treating Hepatitis C: Retreatment of Persons In Whom Prior Therapy Has Failed [İnternet]. Alexandria and Arlington, VA: American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) [erişim 18 Şubat 2014]. http://www. 38
hcvguidelines.org/full-report/retreatment-persons-whom-prior- therapy-has-failed. 133. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, mana- gement, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71.
134. Corey KE, Servoss JC, Casson DR, et al. Pilot study of postex- posure prophylaxis for hepatitis C virus in healthcare workers.
135. Aygen B. Yoğun bakım biriminde çalışanlarda kan ve vücut sıvı- ları ile bulaşan infeksiyonlardan korunma. In: Akalın H, Aygen B, Yalçın AN, eds. İnfeksiyon Hastalıklarında Güncel Durum. İstan- bul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Yayınları, 2009: 141-51. 136. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yaz- danpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infecti- on. Gut. 2009; 58(1): 105-10. [CrossRef] 137. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001; 8(2): 87-95. [CrossRef] 138. Lavanchy D, Steinmann J, Moritz A, Frei PC. Evaluation of a new automated third-generation anti-HCV enzyme immunoassay. J
3.0.CO;2-3">[CrossRef] 139. Lefrere JJ, Roudot-Thoraval F, Lunel F, et al. Expertise of French la- boratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol. 2004; 42(5): 2027-30.
140. Updated U.S. Public Health Service Guidelines for the Mana- gement of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Re- comm Rep. 2001; 50(RR-11): 1-52. 141. Puro V, De Carli G, Cicalini S, et al. European recommendations for the management of healthcare workers occupationally expo- sed to hepatitis B virus and hepatitis C virus. Euro Surveill. 2005; 10(10): 260-4. 142. Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet E, Yazdanpanah Y. Blood-borne viruses in health care workers: prevention and management. J Clin Virol. 2011; 52(1): 4-10. [CrossRef] 143. Ramsay ME. Guidance on the investigation and management of occupational exposure to hepatitis C. PHLS Advisory Committee on Blood Borne Viruses. Commun Dis Public Health. 1999; 2(4): 258-62. 144. Charles PG, Angus PW, Sasadeusz JJ, Grayson ML. Manage- ment of healthcare workers after occupational exposure to he- patitis C virus. Med J Aust. 2003; 179(3): 153-7. Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi 39 Yüklə 369,37 Kb. Dostları ilə paylaş:
|